Novel Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion-Selective Inhibitors for Lung Cancer Therapy.
1/5 보강
This patent describes novel prop-2-ynamide-derived epidermal growth factor receptor (EGFR) inhibitors, which selectively target EGFR exon20 insertion mutations.
APA
Jiang Y, Liang SH (2026). Novel Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion-Selective Inhibitors for Lung Cancer Therapy.. ACS medicinal chemistry letters, 17(3), 611-612. https://doi.org/10.1021/acsmedchemlett.6c00030
MLA
Jiang Y, et al.. "Novel Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion-Selective Inhibitors for Lung Cancer Therapy.." ACS medicinal chemistry letters, vol. 17, no. 3, 2026, pp. 611-612.
PMID
41847659 ↗
Abstract 한글 요약
This patent describes novel prop-2-ynamide-derived epidermal growth factor receptor (EGFR) inhibitors, which selectively target EGFR exon20 insertion mutations. These EGFR inhibitors exhibit therapeutic potential for the treatment of nonsmall cell lung cancer (NSCLC) and other malignancies driven by EGFR mutations.
같은 제1저자의 인용 많은 논문 (5)
- Negative trial but positive lesson: reframing immunotherapy resistance from one-size-fits-all to precision strategies.
- Macrophage deficiency discordantly regulated tumor growth and metastasis through increased thrombospondin-1 production.
- Juglans mandshurica-Eleutherococcus senticosus herb pair inhibits hepatocellular carcinoma growth by inducing immunogenic cell death via the HIF-1α/STAT3 pathway.
- A Cuproptosis-related lncRNA Signature for Prognostic Stratification and Immunotherapeutic Implications in Lung Adenocarcinoma.
- Multi-omics study on tumor-associated macrophages remodeling the tumor microenvironment via the CXCL5-CXCR2 axis to drive immune escape in bladder cancer.